Margin Breakdown
| EBITDA Margin | (2.81) | |
| Gross Margin | 0.33 | |
| Profit Margin | (3.18) |
Our latest forecast of Bionano (NASDAQ:BNGO)
 | By Rifka Kats | Macroaxis Story |
Bionano Genomics Sales per Share is quite stable at the moment as compared to the past year. The company's current value of Sales per Share is estimated at 0.99. Tangible Assets Book Value per Share is expected to rise to 2.44 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (28.5 M). The goal of this thesis is to give institutional investors our take on Bionano future value. We will inspect the reasons why it could be a game-changer for Bionano Genomics institutional investors.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Bionano Genomics is OVERVALUED at 1.71 per share with modest projections ahead. About 6.0% of Bionano Genomics shares are held by institutions such as insurance companies. Insiders ownership of Bionano Genomics refers to the amount of Bionano Genomics equity owned by Bionano officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Bionano, including its current ownership diagnostics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bionano Genomics. Your research has to be compared to or analyzed against Bionano Genomics' peers to derive any actionable benefits. When done correctly, Bionano Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bionano Genomics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Bionano Genomics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Bionano Genomics
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bionano Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Bionano Genomics on a daily basis if you are holding a position in it. Bionano Genomics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Bionano Genomics stock to be traded above the $1 level to remain listed. If Bionano Genomics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Bionano Genomics's Liquidity
Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Bionano Genomics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Bionano Genomics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Bionano Genomics's total debt and its cash.
Bionano Genomics Gross Profit
Bionano Genomics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Bionano Genomics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Bionano Genomics Gross Profit growth over the last 10 years. Please check Bionano Genomics' gross profit and other fundamental indicators for more details.
What is driving Bionano Genomics Investor Appetite?
Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.